#
# List of treatments for testing.  Each line is the following format:
#
# Gene\tVariant\tTumorType\tTreatments\tLevel
#

# Test KIT
KIT	N505I	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib; 1: Ripretinib;
KIT	N505I	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib; 1: Ripretinib;
KIT	N505I	Melanoma	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Ripretinib;
KIT	N505I	Colorectal Cancer	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Ripretinib;
KIT	N505I	Thymic Tumor	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Ripretinib;
KIT	D816A	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib; 1: Ripretinib; 2: Sorafenib; 4: Nilotinib; 4: Pazopanib; R2: Imatinib; R2: Sunitinib;
KIT	D816A	Melanoma	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Sorafenib; 3B: Ripretinib;
KIT	D816A	Colorectal Cancer 3B: Regorafenib; 3B: Sorafenib;
KIT	D816A	Mastocytosis	1: Avapritinib;
KIT	D816A	Thymic Tumor	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Sorafenib; 3B: Ripretinib;
KIT	Y823D	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib; 1: Ripretinib; 2: Sorafenib; 4: Nilotinib; 4: Pazopanib; R2: Imatinib; R2: Sunitinib;
KIT	Y823D	Melanoma	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Sorafenib; 3B: Ripretinib;
KIT	Y823D	Thymic Tumor	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Sorafenib; 3B: Ripretinib;
KIT	Y823D	Colorectal Cancer	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Sorafenib; 3B: Ripretinib;
KIT	Y823G	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib; 1: Ripretinib;
KIT	Y823G	Melanoma	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Ripretinib;
KIT	Y823G	Thymic Tumor	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Ripretinib;
KIT	Y823G	Colorectal Cancer	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Ripretinib;
KIT	A829P	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib; 1: Ripretinib; 2: Sorafenib; 4: Nilotinib; 4: Pazopanib; R2: Imatinib; R2: Sunitinib;
KIT	A829P	Melanoma	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Sorafenib; 3B: Ripretinib;
KIT	A829P	Thymic Tumor	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Sorafenib; 3B: Ripretinib;
KIT	A829P	Colorectal Cancer	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Sorafenib; 3B: Ripretinib;
KIT	D820G	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib; 1: Ripretinib; 2: Sorafenib; 4: Nilotinib; 4: Pazopanib; R2: Imatinib; R2: Sunitinib;
KIT	D820G	Melanoma	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Sorafenib; 3B: Ripretinib;
KIT	D820G	Thymic Tumor	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Sorafenib; 3B: Ripretinib;
KIT	D820G	Colorectal Cancer	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Sorafenib; 3B: Ripretinib;
KIT	D820G	Mastocytosis
KIT	N822E	Gastrointestinal Stromal Tumor	1: Imatinib; 1: Sunitinib; 1: Regorafenib; 1: Ripretinib; 2: Sorafenib; 4: Nilotinib; 4: Pazopanib; R2: Imatinib; R2: Sunitinib;
KIT	N822E	Melanoma	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Sorafenib; 3B: Ripretinib;
KIT	N822E	Thymic Tumor	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Sorafenib; 3B: Ripretinib;
KIT	N822E	Colorectal Cancer	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Sorafenib; 3B: Ripretinib;

# L2 should be included for few exon 11/13 mutations
KIT	L576P	Melanoma	2: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Ripretinib;
KIT	L576P	Colorectal Cancer	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Ripretinib;
KIT	L576P	AML
KIT	V654A	Melanoma	2: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Ripretinib;
KIT	V654A	Colorectal Cancer	3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Ripretinib;
KIT	V654A	AML

MTOR	L2427Q	Renal Clear Cell Carcinoma	3A: Temsirolimus; 4: Everolimus;
PDGFRA	D842I	GIST	1: Avapritinib; 2: Imatinib; 2: Sunitinib; 2: Regorafenib; 2: Ripretinib;
PDGFRA	D842I	Thymic Tumor	3B: Avapritinib; 3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Ripretinib;
PDGFRA	D842V	GIST	R1: Imatinib; 1: Avapritinib; 2: Dasatinib; 2: Sunitinib; 2: Regorafenib; 2: Ripretinib;
PDGFRA	D842V	Thymic Tumor	3B: Avapritinib; 3B: Dasatinib; 3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Ripretinib;
EGFR	A763_Y764insFQEA	NSCLC	1: Amivantamab; 1: Amivantamab+Chemotherapy; 2: Erlotinib; 3A: Poziotinib; 3A: Zipalertinib; 4: Afatinib;
# this one overlaps with A763_Y764insFQEA, but the rule only applies to exact match, so R1 will be used
EGFR	Y764_D770dup	NSCLC	R1: Erlotinib; R1: Gefitinib; R1: Afatinib; 1: Amivantamab; 1: Amivantamab+Chemotherapy; 3A: Poziotinib; 3A: Zipalertinib;
# this one does not overlap with A763_Y764insFQEA, so R1 for sure
EGFR	N771delinsSTH	Lung Adenocarcinoma	R1: Erlotinib; R1: Gefitinib; R1: Afatinib; 1: Amivantamab; 1: Amivantamab+Chemotherapy; 3A: Poziotinib; 3A: Zipalertinib;

# test cases cover the resistance treatment should overwrite sensitive from alternative allele
ABL1	T315I	Chronic Myelogenous Leukemia	R1: Imatinib; R1: Dasatinib; R1: Nilotinib; R1: Bosutinib; 1: Ponatinib; 1: Asciminib;
ABL1	T315I	Melanoma

ABL1	T315A	Chronic Myelogenous Leukemia	R1: Dasatinib; R1: Imatinib; 2: Bosutinib; 2: Nilotinib;
ABL1	T315A	Melanoma

ABL1	T315V	Chronic Myelogenous Leukemia
ABL1	T315V	Melanoma

# test few more resistance treatments
PDGFRA	D842V	Gastrointestinal Stromal Tumor	R1: Imatinib; 1: Avapritinib; 2: Dasatinib; 2: Sunitinib; 2: Regorafenib; 2: Ripretinib;
PDGFRA	D842V	Melanoma	3B: Avapritinib; 3B: Dasatinib; 3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Ripretinib;
PDGFRA	D842H	Gastrointestinal Stromal Tumor	1: Avapritinib; 2: Imatinib; 2: Sunitinib; 2: Regorafenib; 2: Ripretinib;
PDGFRA	D842H	Melanoma	3B: Avapritinib; 3B: Imatinib; 3B: Sunitinib; 3B: Regorafenib; 3B: Ripretinib;
BTK	C481S	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	R1: Ibrutinib;
BTK	C481Y	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	R2: Ibrutinib;

# this is R2 in production but the R2 data is not ready for public release yet
BTK	T316A	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	R2: Ibrutinib;

# Test Heme
FLT3	Internal Tandem Duplication	AML	1: Gilteritinib; 1: Quizartinib; 1: Midostaurin+High Dose Chemotherapy; 3A: Sorafenib; 3A: Crenolanib;
FLT3	Internal Tandem Duplication	APLPMLRARA	1: Gilteritinib; 1: Quizartinib; 1: Midostaurin+High Dose Chemotherapy; 3A: Sorafenib; 3A: Crenolanib;
FLT3	Internal Tandem Duplication	Colorectal Cancer
SF3B1	K700E	AML	4: Emavusertib;
SF3B1	K700E	AMLNOS	4: Emavusertib;
SF3B1	K700E	APLPMLRARA	4: Emavusertib;
SF3B1	K700E	Colorectal Cancer
DNMT3A	P904L	AML
DNMT3A	P904L	APLPMLRARA
DNMT3A	P904L	CMML
DNMT3A	P904L	Colorectal Cancer
ABL1	BCR-ABL1 Fusion	BLL	1: Imatinib; 1: Dasatinib; 1: Ponatinib; 2: Bosutinib; 2: Nilotinib;
ABL1	BCR-ABL1 Fusion	BLLNOS	1: Imatinib; 1: Dasatinib; 1: Ponatinib; 2: Bosutinib; 2: Nilotinib;
ABL1	BCR-ABL1 Fusion	BLLBCRABL1	1: Imatinib; 1: Dasatinib; 1: Ponatinib; 2: Bosutinib; 2: Nilotinib;
ABL1	BCR-ABL1 Fusion	Colorectal Cancer
ABL1	E255K	CML	R1: Imatinib; R1: Nilotinib; 2: Bosutinib; 2: Dasatinib;
ABL1	E255K	CMLBCRABL1	R1: Imatinib; R1: Nilotinib; 2: Bosutinib; 2: Dasatinib;
ABL1	E255K	AML
ABL1	E255K	Colorectal Cancer
ABL1	E255D	CML
ABL1	E255D	CMLBCRABL1
ABL1	E255D	AML
ABL1	E255D	Colorectal Cancer
KMT2	KMT2-MLLT3 Fusion	AML
KMT2	KMT2-MLLT3 Fusion	APLPMLRARA
KMT2	KMT2-MLLT3 Fusion	Colorectal Cacner
PDGFRB	PDGFRB-CSF1R Fusion	CMML	1: Imatinib;
PDGFRB	PDGFRB-CSF1R Fusion	Colorectal Cancer
BRAF	K601E	Colorectal Cancer	3B: Trametinib; 4: Plixorafenib;
ARAF	S214A	HDCN	3A: Sorafenib; 3A: Cobimetinib; 3A: Trametinib;
ARAF	S214A	ECD	2: Cobimetinib; 2: Trametinib; 3A: Sorafenib;
#ARAF	S214A	RDD
ARAF	S214A	Colorectal Cancer	3B: Sorafenib;
TP53	K292T	AML
TP53	K292T	APLPMLRARA
TP53	K292T	Colorectal cancer

# Test solid/liquid propagation
ABL1	BCR-ABL1 Fusion	B-Lymphoblastic Leukemia/Lymphoma	1: Imatinib; 1: Dasatinib; 1: Ponatinib; 2: Bosutinib; 2: Nilotinib;
ABL1	BCR-ABL1 Fusion	Chronic Myelogenous Leukemia	1: Imatinib; 1: Nilotinib; 1: Dasatinib; 1: Bosutinib; 1: Asciminib;
ABL1	BCR-ABL1 Fusion	Acute Myeloid Leukemia
IDH1	R132H	Acute Myeloid Leukemia	1: Ivosidenib; 1: Olutasidenib;
IDH1	R132H	Glioblastoma	3A: Ivosidenib; 3B: Vorasidenib;
IDH1	R132H	B-Lymphoblastic Leukemia/Lymphoma
IDH1	R132H	Therapy-Related Acute Myeloid Leukemia	1: Ivosidenib; 1: Olutasidenib;
IDH2	R172K	Acute Myeloid Leukemia	1: Enasidenib;
IDH2	R172K	Melanoma	3B: Vorasidenib;
MAP2K1	K57N	Erdheim-Chester Disease	2: Cobimetinib; 2: Trametinib;
MAP2K1	K57N	Lung Adenocarcinoma	3A: Trametinib; 3A: Cobimetinib;
MAP2K1	K57N	Glioblastoma	3B: Trametinib; 3B: Cobimetinib;
#MAP2K1	K57N	Diffuse Large B-Cell Lymphoma, NOS
PIK3CA	E545K	Breast Cancer	1: Alpelisib+Fulvestrant; 1: Inavolisib+Palbociclib+Fulvestrant; 1: Capivasertib+Fulvestrant; 4: RLY-2608; 4: RLY-2608+Fulvestrant;
PIK3CA	E545K	Ovarian Cancer	3B: Alpelisib+Fulvestrant; 3B: Inavolisib+Palbociclib+Fulvestrant; 3B: Capivasertib+Fulvestrant; 4: RLY-2608;
#PIK3CA	E545K	Acute Myeloid Leukemia
NRAS	G12C	Breast Cancer	3B: Binimetinib;
#NRAS	G12C	Chronic Myelogenous Leukemia
SF3B1	R625G	Chronic Myelomonocytic Leukemia	4: Ceralasertib;
SF3B1	R625G	Breast Cancer

# Sotorasib should only work for KRAS G12C, not alternative allele
# the following tests should be enabled when the liquid propagation is in production also the AGM-510 treatment is in place
KRAS	G12C	Breast Cancer	3B: Adagrasib+Cetuximab; 3B: Adagrasib+Panitumumab; 3B: Avutometinib+Defactinib; 3B: Sotorasib; 3B: Adagrasib; 3B: Sotorasib+Cetuximab; 3B: Sotorasib+Panitumumab; 4: Trametinib; 4: Cobimetinib; 4: Binimetinib;
KRAS	G12D	Breast Cancer	3B: Avutometinib+Defactinib; 4: Daraxonrasib; 4: MRTX-1133; 4: Trametinib; 4: ASP3082; 4: Cobimetinib; 4: Binimetinib;
KRAS	G12C	NSCLC	1: Sotorasib; 1: Adagrasib; 3B: Adagrasib+Cetuximab; 3B: Adagrasib+Panitumumab; 3B: Avutometinib+Defactinib; 3B: Sotorasib+Cetuximab; 3B: Sotorasib+Panitumumab; 4: Trametinib; 4: Cobimetinib; 4: Binimetinib;
KRAS	G12D	NSCLC	3A: ASP3082; 3A: Daraxonrasib; 3B: Avutometinib+Defactinib; 4: MRTX-1133; 4: Trametinib; 4: Cobimetinib; 4: Binimetinib;
KRAS	G12C	Colorectal Cancer	R1: Cetuximab; R1: Panitumumab; R1: Tucatinib+Trastuzumab; 1: Adagrasib+Cetuximab; 1: Sotorasib+Panitumumab; 2: Adagrasib+Panitumumab; 2: Sotorasib+Cetuximab; 3B: Avutometinib+Defactinib; 3B: Sotorasib; 3B: Adagrasib; 4: Trametinib; 4: Cobimetinib; 4: Binimetinib;
KRAS	G12D	Colorectal Cancer	R1: Cetuximab; R1: Panitumumab; R1: Tucatinib+Trastuzumab; 3B: Avutometinib+Defactinib; 4: Daraxonrasib; 4: MRTX-1133; 4: Trametinib; 4: ASP3082; 4: Cobimetinib; 4: Binimetinib;
KRAS	G12C	AML
KRAS	G12D	AML
KRAS	G12C	Leukemia
KRAS	G12D	Leukemia
BRAF	V600E	Anaplastic Thyroid Cancer	1: Dabrafenib+Trametinib; 3B: Dabrafenib; 3B: Encorafenib+Cetuximab; 3B: Encorafenib+Cetuximab+FOLFOX Regimen; 3B: Selumetinib; 3B: Tovorafenib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Encorafenib+Panitumumab; 3B: Trametinib; 3B: Vemurafenib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF	V600K	Anaplastic Thyroid Cancer	3B: Dabrafenib+Trametinib; 3B: Tovorafenib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Trametinib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF	V600E	Melanoma	1: Dabrafenib; 1: Dabrafenib+Trametinib; 1: Vemurafenib+Atezolizumab+Cobimetinib; 1: Trametinib; 1: Vemurafenib; 1: Vemurafenib+Cobimetinib; 1: Encorafenib+Binimetinib; 3B: Encorafenib+Cetuximab; 3B: Encorafenib+Cetuximab+FOLFOX Regimen; 3B: Selumetinib; 3B: Tovorafenib; 3B: Encorafenib+Panitumumab;
BRAF	V600K	Melanoma	1: Dabrafenib+Trametinib; 1: Vemurafenib+Atezolizumab+Cobimetinib; 1: Trametinib; 1: Vemurafenib+Cobimetinib; 1: Encorafenib+Binimetinib; 3B: Tovorafenib;
BRAF	V600G	Melanoma	1: Vemurafenib+Atezolizumab+Cobimetinib; 2: Encorafenib+Binimetinib; 2: Dabrafenib+Trametinib; 2: Vemurafenib+Cobimetinib; 3B: Tovorafenib;
BRAF	V600E	NSCLC	1: Dabrafenib+Trametinib; 1: Encorafenib+Binimetinib; 3B: Dabrafenib; 3B: Encorafenib+Cetuximab; 3B: Encorafenib+Cetuximab+FOLFOX Regimen; 3B: Selumetinib; 3B: Tovorafenib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Encorafenib+Panitumumab; 3B: Trametinib; 3B: Vemurafenib; 3B: Vemurafenib+Cobimetinib;
BRAF	V600K	NSCLC	3B: Dabrafenib+Trametinib; 3B: Tovorafenib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Trametinib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF	V600G	NSCLC	3B: Encorafenib+Binimetinib; 3B: Tovorafenib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Dabrafenib+Trametinib; 3B: Vemurafenib+Cobimetinib;
BRAF	V600E	Colorectal Cancer	1: Encorafenib+Cetuximab; 1: Encorafenib+Cetuximab+FOLFOX Regimen; 2: Encorafenib+Panitumumab; 3B: Dabrafenib; 3B: Dabrafenib+Trametinib; 3B: Selumetinib; 3B: Tovorafenib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Trametinib; 3B: Vemurafenib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF	V600K	Colorectal Cancer	3B: Dabrafenib+Trametinib; 3B: Tovorafenib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Trametinib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF	V600E	HCL	2: Vemurafenib;
BRAF	V600K	Pilocytic Astrocytoma   3B: Dabrafenib+Trametinib; 3B: Trametinib; 3B: Vemurafenib+Cobimetinib; 3B: Encorafenib+Binimetinib;
BRAF	V600E	Pilocytic Astrocytoma	1: Dabrafenib+Trametinib; 2: Selumetinib; 2: Vemurafenib+Cobimetinib; 3B: Dabrafenib; 3B: Encorafenib+Cetuximab; 3B: Encorafenib+Cetuximab+FOLFOX Regimen; 3B: Tovorafenib; 3B: Vemurafenib+Atezolizumab+Cobimetinib; 3B: Encorafenib+Panitumumab; 3B: Trametinib; 3B: Vemurafenib; 3B: Encorafenib+Binimetinib;
BRAF	V600K	HCL
AKT1	E17K	Breast Cancer   1: Capivasertib+Fulvestrant; 3B: Capivasertib;
AKT1	E17K	NSCLC   3B: Capivasertib; 3B: Capivasertib+Fulvestrant;
AKT1	E17G	Breast Cancer   1: Capivasertib+Fulvestrant;
FGFR3	Y373C	Bladder Cancer	1: Erdafitinib; 4: Fexagratinib;
FGFR3	Y373G	Bladder Cancer	2: Erdafitinib; 4: Fexagratinib;
EGFR	A750P	NSCLC
EGFR	A750G	NSCLC
MTOR	E2014K	Bladder Cancer	3A: Everolimus; 4: Temsirolimus;
MTOR	E2014L	Bladder Cancer	4: Everolimus; 4: Temsirolimus;
MTOR	E2014K	NSCLC	3B: Everolimus; 4: Temsirolimus;
ABL1	Y253H	CML	R1: Imatinib; R1: Nilotinib; 2: Bosutinib; 2: Dasatinib;
ABL1	Y253H	TLL
ABL1	Y253M	CML
BRAF	L597R	Melanoma	3A: Trametinib; 4: Plixorafenib;
BRAF	L597M	NSCLC	3B: Trametinib; 4: Plixorafenib;
EGFR	L861Q	NSCLC	1: Afatinib; 2: Dacomitinib; 2: Erlotinib; 2: Osimertinib; 2: Gefitinib; 2: Amivantamab+Chemotherapy; 3A: Patritumab Deruxtecan; 3A: Amivantamab+Lazertinib;
EGFR	L861R	NSCLC
EGFR	L861M	NSCLC
EGFR	G724S	NSCLC	3A: Afatinib; R2: Osimertinib;
EGFR	G724S	MEL	3B: Afatinib;
KRAS	G12C	NSCLC	1: Sotorasib; 1: Adagrasib; 3B: Adagrasib+Cetuximab; 3B: Adagrasib+Panitumumab; 3B: Avutometinib+Defactinib; 3B: Sotorasib+Cetuximab; 3B: Sotorasib+Panitumumab; 4: Trametinib; 4: Cobimetinib; 4: Binimetinib;
KRAS	G12C	Melanoma	3B: Adagrasib+Cetuximab; 3B: Adagrasib+Panitumumab; 3B: Avutometinib+Defactinib; 3B: Sotorasib; 3B: Adagrasib; 3B: Sotorasib+Cetuximab; 3B: Sotorasib+Panitumumab; 4: Trametinib; 4: Cobimetinib; 4: Binimetinib;
KRAS	G12A	NSCLC	3A: Daraxonrasib; 3B: Avutometinib+Defactinib; 4: Trametinib; 4: Cobimetinib; 4: Binimetinib;
KRAS	G12A	Melanoma	3B: Avutometinib+Defactinib; 4: Daraxonrasib; 4: Trametinib; 4: Cobimetinib; 4: Binimetinib;
KRAS	G12C	Histiocytosis	3A: Cobimetinib; 3A: Trametinib;
KRAS	G12A	Histiocytosis	3A: Cobimetinib; 3A: Trametinib;
IDH1	R132H	AML	1: Ivosidenib; 1: Olutasidenib;
IDH1	R132G	AML	1: Ivosidenib; 1: Olutasidenib;
FGFR2	FGFR2-BICC1 Fusion	Cholangiocarcinoma	1: Pemigatinib; 1: Futibatinib; 3A: Lirafugratinib; 3B: Erdafitinib; 4: Fexagratinib;
ERBB2	Amplification	Breast Cancer	1: Trastuzumab; 1: Trastuzumab+Chemotherapy; 1: Ado-Trastuzumab Emtansine; 1: Lapatinib+Capecitabine; 1: Lapatinib+Letrozole; 1: Trastuzumab+Pertuzumab+Chemotherapy; 1: Neratinib; 1: Neratinib+Capecitabine; 1: Trastuzumab+Tucatinib+Capecitabine; 1: Trastuzumab Deruxtecan; 1: Margetuximab+Chemotherapy; 3B: Trastuzumab+Carboplatin-Taxol Regimen; 3B: Trastuzumab+Pertuzumab; 3B: Lapatinib+Trastuzumab; 3B: Trastuzumab+Docetaxel; 3B: Zanidatamab; 3B: Pembrolizumab+Trastuzumab+Chemotherapy; 3B: Tucatinib+Trastuzumab;
ERBB2	Amplification	Colorectal Cancer	1: Tucatinib+Trastuzumab; 2: Trastuzumab+Pertuzumab; 2: Lapatinib+Trastuzumab; 2: Trastuzumab Deruxtecan; 3B: Trastuzumab; 3B: Trastuzumab+Carboplatin-Taxol Regimen; 3B: Trastuzumab+Chemotherapy; 3B: Trastuzumab+Docetaxel; 3B: Zanidatamab; 3B: Ado-Trastuzumab Emtansine; 3B: Pembrolizumab+Trastuzumab+Chemotherapy; 3B: Lapatinib+Capecitabine; 3B: Lapatinib+Letrozole; 3B: Trastuzumab+Pertuzumab+Chemotherapy; 3B: Neratinib; 3B: Neratinib+Capecitabine; 3B: Trastuzumab+Tucatinib+Capecitabine; 3B: Margetuximab+Chemotherapy;
RET	KIF5B-RET Fusion	NSCLC	1: Selpercatinib; 1: Pralsetinib; 2: Cabozantinib; 3A: Vandetanib;
RET	KIF5B-RET Fusion	Bladder Cancer	1: Selpercatinib; 3B: Cabozantinib; 3B: Vandetanib; 3B: Pralsetinib;
MET	Amplification	Non-Small Cell Lung Cancer	2: Crizotinib; 2: Capmatinib; 2: Tepotinib; 3A: Telisotuzumab Vedotin; R2: Erlotinib; R2: Gefitinib; R2: Osimertinib;

# Check the exclusion rule. Example： Oncogenic Mutations {excluding V600}
BRAF	V600E	Erdheim-Chester Disease	1: Vemurafenib; 3A: Dabrafenib;
BRAF	K601E	Erdheim-Chester Disease	2: Cobimetinib; 2: Trametinib;
ARAF	S214C	Erdheim-Chester Disease	2: Cobimetinib; 2: Trametinib; 3A: Sorafenib;
ARAF	S214C	Langerhans Cell Histiocytosis	2: Cobimetinib; 2: Trametinib; 3A: Sorafenib;


# Check resistance mutation
ALK	G1202R	NSCLC	2: Lorlatinib; 3A: NVL-655; R2: Alectinib; R2: Crizotinib; R2: Ceritinib; R2: Brigatinib;
